ScheringPlough Corp  (SGP) Trade Now »     Rate SGP  -  Discuss SGP  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

SGP: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP SGP

73%

<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin... Continue reading »

Schering-Plough Corp. SGP

62%

Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide. It operates in three segments: Human Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. Human Prescription Pharmaceuticals segment offers human pharmaceutical products in six therapeutic areas, including cardiovascular, central nervous system, immunology and infectious disease, oncology, respiratory, and women’s health. This segment sells its products through sales representatives to hospitals, managed care organizations, wholesale distributors, and retail pharmacists. Ani< /><><><><><><>< /><><><><><><><><><><>< /><><><><><><><><><><><><><><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />< /><><><><><><><><><><>< /><><><><>< /><><><><>< /><><><><>< /><><><><>< />... Continue reading »

IBD #14 SGP

46%

Continue reading »

New Index for Pet Care and Animal 'Farma' SGP

73%

New Index for Pet Care and Animal 'Farma' By Mike Havrilla on 2/7/09 ETF Innovators   This past week, CNBC's Trish Regan took an in-depth look at the pet industry and Westminster Dog Show (which runs Feb. 7-16), which attracts millions of viewers and thousands of dogs and pet owners vying to earn the Best in Show designation. Late last year, Ladenburg Thalmann analyst Nancy Hull appeared on CNBC talking about PetMed Express (PETS) and the recession-resistant nature of the pet med business.   <> PETS turned out to be a good call – the stock <><><><><><><><><><><><><><><><><><>... Continue reading »

A Backlog of Decisions is Building at the FDA SGP

73%

A Backlog of Decisions is Building at the FDA <> The accompanying table presents 70 FDA product approval decision dates along with the market caps and one year stock price change for the underlying companies. A note of caution for investors and traders is that the most common outcome from the FDA in the past year has been a delay in decisions due to understaffed conditions at the agency. However, several companies have pending decisions which are likely to occur either before year-end or early next year and will have a major impact on their stock prices. Disco... Continue reading »

From the Blogosphere

Big Pharma & Biotech – Industry Outlook

38%

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co... Continue reading »

Big Pharma & Biotech – Zacks Analyst Interviews

38%

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co... Continue reading »

Big Pharma and Biotech – Industry Outlook

38%

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co... Continue reading »

Approval for Merck-SGP Merger – Analyst Blog

38%

Recently, Merck (MRK) and Schering-Plough (SGP) received approval from the US Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger. However, the transaction has yet to receive approval from other regulators, including China and Mexico. The deal was approved by the European Union antitrust regulators last week. Shareholders of both the companies have already approved the deal in August. Merck expects to close the proposed merger by year end. The FTC approval has come with the condition that both companies will sell som... Continue reading »

Notable Mergers and Acquisitions of the Day: MRK/SGP, SNS, CDCS

<> Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) Receive Approval From European Commission for Merger. <>The Steak n Shake Company (NYSE: SNS), and Western Sizzlin Corporation (NASDAQ: WEST), today jointly announced that they had executed an agreement for a wholly-owned subsidiary of Steak n Shake to merge with and into Western.Western has also declared a special dividend payable to Western stockholders in the form of 1,322,806 shares of Steak n Shake common stock presently beneficially owned by an investment subsidiary of Western. Together, the dividend and (if and when completed) the merg... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.